



Press Release Humedics

BioMedInvest-II LP joins Humedics Series C financing and increases financing round to 7 million Euro

Berlin, Germany, December 17, 2014 – Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that BioMedInvest-II LP complementary joins the Series C financing round now totaling more than 7 million Euro. Humedics' business model, products and company development has attracted another international investor.

Switzerland-based BioMedPartners with their BioMedInvest-II LP fund joins as co-lead the newly formed syndicate of investors in follow up of the recent announcement of the Humedics' Series C financing round that was led by two international investors, Vesalius Biocapital Partners and Seventure Partners.

BioMedInvest-II LP invests in innovative early- to mid-stage companies that have the potential to achieve exceptional growth driven by novel technologies with unique advantages over current products. Humedics therefore perfectly fits into this portfolio with their medical device, the diagnostic drug and the clinically demonstrated significant added value of the LiMAX test in liver disease and liver surgery. BioMedInvest-II LP will be represented on the Humedics Board by Dr. Karsten Fischer.

The raised capital will be used for the European market entry of Humedics' proprietary LiMAX test and the corresponding FLIP diagnostic device. This breath test based diagnostic system represents a revolution in functional liver diagnostics by enabling clinicians to quantitatively determine the individual liver function capacity for a patient within minutes. It allows for better risk assessment in liver surgery and thus, superior surgery planning as well as selecting treatment strategies optimally adapted to the individual patients liver status. The LiMAX test provides certainty for the physician, safety for the patient and leads to cost reduction for the hospital.

Erwin de Buijzer, Managing Director of Humedics GmbH and private co-investor in the financing round, states: "2014 has been a highly successful year for us. The closing of the series C financing round provides the financial basis for preparing a successful launch of our LiMAX test. Feedback from customers is extremely positive and confirms the dramatic reduction of mortality after liver surgery in the centers that use the LiMAX test. We are very pleased with the support from all investors, which enables us to commercialize one of the major innovations in liver function testing."

Please find more details on Humedics' series C financing round and investors in our press release from November 10, 2014, http://humedics.eu/files/20141110_humedics_press_release_c-round.pdf.

About Humedics

Humedics has developed a breath test based diagnostic system (LiMAX test), which comprises a CE-marked medical device, breath masks and a diagnostic drug. More than 100 million people world-

wide suffer from liver diseases (i.e. cirrhosis, hepatitis, fatty liver, metabolic disorders and liver tumors). The LiMAx test enables the clinician to quantitatively determine the individual liver function capacity for a patient within minutes. This allows for selection of treatment strategies that are optimally adapted to the individual patients liver status. Current applications include diagnosis of the liver function before and after liver transplantation, liver surgery planning (e.g. assessment of the amount of liver to be resected without potentially increasing the risk of liver failure) and assessment of diseases such as liver cirrhosis. The LiMAx test has been used more than 12,500 times in clinical practice. Results have been published in highly respected scientific journals. For the approval of the LiMAx test Humedics is presently conducting a phase III multi-center clinical trial. Results are expected mid 2015.

LiMAx Test

The underlying principle of the LiMAx test involves the following steps: Firstly, the diagnostic drug solution is administered intravenously and the drug is metabolized in the liver to paracetamol and $^{13}\text{CO}_2$. The latter is exhaled in the breath. The exhaled air is collected via a respiratory mask. Subsequent continuous measurement of $^{13}\text{CO}_2$ in the patients' breath using laser detection in the FLIP device provides a quantitative determination of the liver capacity and thus reflects the liver function.

About BioMedPartners

BioMedPartners AG is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. We target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

The team consists of experienced investment professionals with extensive expertise in investing and building healthcare companies. In addition, our team is supported by a dedicated team of seasoned senior scientific and business advisors and has access to a broad network within academia, finance and industry. We take an active role in the development of our portfolio companies as a lead investor or as an active syndicate partner.

BioMed's investors represent leading international enterprises and institutions.

www.biomedvc.com

Humedics Contact:

Humedics GmbH

Erwin de Buijzer MD MBA

Marie-Elisabeth-Lüders Str. 1

10625 Berlin

Phone: +49 30 590083240

E-Mail: info@humedics.de

Homepage: www.humedics.de

PR Contact:

Almut Gebhard

Strategische Kommunikation

Hasenheide 56

10967 Berlin

Phone: +49 (0)30 - 6120 1081

Mobile +49 (0)174 3017754

E-Mail: ag@almutgebhard.de